Company Overview - Seer, Inc. is a pioneer in deep, unbiased proteomic insights, setting a standard in the field with its innovative technologies [3] - The company offers the Proteograph Product Suite, which integrates engineered nanoparticles, automation instrumentation, consumables, and analytical software to address challenges in traditional proteomics [3] Upcoming Financial Results - Seer, Inc. will report its financial results for the second quarter of 2025 on August 6, 2025 [1] - A conference call will be webcast starting at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time [1] Webcast Information - Live audio of the webcast will be accessible on the Investor section of Seer's website [2] - An archived replay of the event will be available on the company's website after the live event [2]

Core Insights - Seer, Inc. has launched the Proteograph Product Suite, which includes the Proteograph ONE Assay and SP200 Automation Instrument, aimed at enhancing mass spectrometry-based proteomics for large-scale studies [1][2][3] Product Launch and Features - The new Proteograph workflow significantly improves scalability, reproducibility, and affordability of deep proteomic analysis, addressing historical limitations in the industry [2][4] - The streamlined workflow can process over 1,000 samples per week on a single SP200 instrument, doubling throughput without compromising performance [7] - The per-sample cost of proteomic analysis has been reduced by approximately 60% compared to the initial release in 2021, making population-scale mass spectrometry proteomics more accessible [3][7] Impact on Research - The Proteograph ONE workflow enables large-scale biomarker discovery, longitudinal disease studies, and comprehensive multi-center research, facilitating advances in personalized medicine [4][8] - The product suite is expected to drive significant advancements in understanding complex diseases such as Alzheimer's and cancer, as showcased at the ASMS 2025 conference [6][10] Scientific Collaboration and Data Presentation - Seer and its collaborators will present new scientific data at the ASMS 2025, highlighting the transformative impact of the Proteograph Product Suite in various research areas [6][10] - Notable presentations will include studies on dementia classification and cancer biomarker discovery, demonstrating the practical applications of the new technology [10][12] Availability - The Proteograph Product Suite will be commercially available starting June 1, with options for instrument and kit purchases as well as services through the Seer Technology Access Center [13]